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The human c-mpl gene (MPL) plays an important role in the development of megakaryocytes and platelets as well
as the self-renewal of haematopoietic stem cells. However, numerous MPL mutations have been identified in
haematopoietic diseases. These mutations alter the normal regulatory mechanisms and lead to autonomous
activation or signalling deficiencies. In this review, we summarise 59 different MPL mutations and classify these
mutations into four different groups according to the associated diseases and mutation rates. Using this
classification, we clearly distinguish four diverse types of MPL mutations and obtain a deep understand of their
clinical significance. This will prove to be useful for both disease diagnosis and the design of individual therapy
regimens based on the type of MPL mutations.
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The human c-mpl gene (MPL), a cellular homologue of
the oncogene v-mpl, belongs to the haematopoietic recep-
tor superfamily [1,2]. The protein encoded by MPL,
CD110, is a 635-amino acid protein consisting of four
functional domains: the putative signal peptide, the extra-
cellular domain, the transmembrane domain and the
intracellular domain. These domains correspond to exon
1, exons 2-9, exon 10 and exons 11-12, respectively [3].
In the absence of the CD110 ligand, thrombopoietin
(TPO), the extracellular domain, transmembrane domain
and an amphipathic motif, KWQFP, localised at the
transmembrane-cytoplasmic junction, retain CD110 in
the inactive state [4-6]. When TPO binds to CD110,
CD110 is dimerised and the tyrosine kinases JAK2 and
TYK2 become activated, which in turn triggers the activa-
tion of downstream positive signalling pathways, including
JAK-STAT/Crkl, SHP2-Bad, SHC-MAPK, and PLC-PKC
[7-19]. It has been suggested that CD110 and TPO play an
important role in the development of megakaryocytes and
platelets as well as the self-renewal of haematopoietic
stem cells [3,20,21].* Correspondence: zrxzzz@126.com
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reproduction in any medium, provided the orHowever, various MPL mutations alter the normal regu-
latory mechanisms; some may cause a complete or partial
loss of CD110 function, thus leading to thrombocytopenia,
while other types of mutations result in the autonomous ac-
tivation of CD110 and the development of thrombocytosis
(Summarised in Figure 1).Several MPL mutations have been identified in
association with haematopoietic diseases
Since the first two heterozygous MPL point mutations
were identified in congenital amegakaryocytic throm-
bocytopenia (CAMT) in 1999, mutations in hereditary
thrombocythaemia (HT), myeloproliferative neoplasms
(MPNs), refractory anaemia with ringed sideroblasts
associated with marked thrombocytosis (RARS-t) and
acute myeloid leukaemia (AML) have been identified
[22]. CAMT is a rare inherited disorder that presents
with thrombocytopenia at birth, which eventually pro-
gresses into pancytopenia without physical malforma-
tions. MPL mutations associated with this disease are
autosomal, recessive germline mutations, which play a
decisive role in the course of the disease [23,24].
According to the data collected by Ballmaier et al.,
we calculated the mutation rate of the MPL gene to
reach as high as 91.8% (56 out of 61 CAMT patients
for whom MPL sequencing revealed MPL mutations);
no mutations other than those found in the MPLThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A schematic summary of the mechanism that different mutations of human c-mpl gene (MPL) bring about distinct biological
effects. Type 1 mutation: MPL mutations found in CAMT. Type 2 mutation: MPL-S505N、K39N、 P106L mutations found in HT. Type 3
mutation: MPL-W515L and W515K mutations found in MPNs, RARS-t and AML. Type 4 mutation: MPL-W515A, W515R, W515-P518delinsKT,
Y591D, A519T, L510P, A506T, T487A, Y252H, S204P, S204F, IVS 11/12 and IVS 10/11.
He et al. Journal of Hematology & Oncology 2013, 6:11 Page 2 of 8
http://www.jhoonline.org/content/6/1/11gene have been identified in CAMT patients [25].
HT, a hereditary disease of thrombocythaemia, is the
second disease that was shown to be associated with
MPL mutations. The MPL mutations detected in HT
patients, S505N, K39N and P106L, are also germline
mutations. These mutations are inherited in a number
of ways: autosomal dominant inheritance, autosomal
dominant inheritance with incomplete penetrance and
autosomal recessive inheritance with possible mild
heterozygote manifestation, respectively. Various soma-
tic mutations, such as MPL-W515L, W515K, W515A,
W515R, and W515-P518delinsKT, have also been
detected in MPN samples, such as polycythaemia vera
(PV), primary myelofibrosis (PMF) and essential thrombo-
cythaemia (ET), which manifest as the overproduction of
one or more myeloid lineages.Classification of MPL mutations
We reviewed relevant papers published from 1999 to
2012 and found that 59 different MPL mutations have
been reported. According to the frequency of MPL
mutations and the associated clinical conditions, such as
inheritance pattern, diagnosis, clinical manifestation and
laboratory results, we categorised these mutations into
four different groups as follows (summarised in Table 1):
Type1. MPL mutations found in CAMT;
Type 2. MPL - S505N, K39N and P106L mutations
found in HT;
Type 3. MPL - W515L and W515K mutations found in
MPNs, RARS-t and AML;
Type 4. Other MPL mutations: MPL-W515A, W515R,
W515-P518delinsKT, Y591D, A519T, L510P, A506T,
Table 1 Classfication and clinical features of MPL mutations indentified in hematopoietic diseases
Mutation type Mutation and Inheritance pattern Effect clinical
manifestation









Thrombocytopenia CAMT (about 91.8%) (25-30)





Thrombocytosis HT (about 54.5%) (22,24,34,35)
K39N,P106L Autosomal dominant with incomplete
penetrance and autosomal recessive with






Thrombocytosis HT (7% of African-American
individuals and 6% of Arab
individuals)
(40,41)
Type 3 W515L/K Somatic mutation Autonomous
activate MPL
function
Thrombocytosis MPNs (about1% in ET and 5%























IVS 11/12 and IVS
10/11
Somatic mutation Unclear Unknown Rare in MPNs (72-74)
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MPL mutations found in CAMT
Currently, 41 different MPL mutations have been detected
in CAMT samples [25]. They can be classified into non-
sense mutations, deletions and frameshift mutations, mis-
sense mutations and splice site mutations. Ballmaier et al.
analysed 9 patients with CAMT and found that the types
of MPL mutations correlated with the clinical course of
the disease [26]. King then proposed a new classification
of CAMT, type I and type II, based on the course of the
disease and the types of MPL mutations [27].
CAMT type I is characterised by persistently low
platelet counts and early progression to bone marrow
failure. Nonsense, deletions and frameshift MPL muta-
tions, such as MPL c.127C>T and c.378delT, may be
responsible for this disease type, as these mutations
introduce premature stop codons and thus cause a
complete loss of CD110 function [28]. In in vitro assays,
CD110 is not expressed in K562 cells with nonsense
mutations; therefore, no TPO-driven signalling can be
detected [29]. Colony assays have also revealed that the
total number of colony forming cells derived from
CAMT I patients with nonsense mutations was signifi-
cantly reduced compared with normal donors [28].CAMT II displays a less aggressive course with a transi-
ent increase in platelet counts during the first year and
delayed or no progression of pancytopenia. Additionally,
types of missense and splice site MPL mutations, such as
the most frequent mutation, c.305G>C, are closely asso-
ciated with CAMT II. This is because these mutations
cause amino acid changes or mRNA splicing defects in
CD110, which do not completely abrogate the function of
CD110 but leave residual activity [28-30]. Two lines of evi-
dence support this hypothesis: 1. TPO-driven signalling is
significantly reduced but not eliminated in K562 cells with
missense mutations in in vitro assays [29] and 2. Colony-
forming cells derived from CAMT II patients with mis-
sense mutations remain reactive to TPO [28].
In general, several studies have confirmed the genotype-
phenotype correlation in CAMT [28,31,32]. However, as
few reports discuss the relationship between MPL muta-
tions and brain abnormalities, malignant transformation in
CAMT is still unclear [23,32,33]. Due to the causative func-
tion of MPL mutations, especially nonsense mutations, in
CAMT, gene therapy aimed to correct CD110 deficiency
seems possible.
MPL-S505N, K39N, and P106L mutations associated with HT
MPL-S505N is an activating mutation that was first
detected by Ding et al. in all members of a specific Japanese
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fected with the mutant type (S505N) but not the wild type
DNA survived, even without growth factor stimulation
[22]. Additionally, a study has demonstrated the constitu-
tive activation of downstream signals without factor de-
pendence in both Ba/F3 cells with the S505N mutation and
platelets of the S505N mutant derived from HT patients
[22]. How does MPL-S505N induce ligand-independent
phosphorylation of downstream signalling molecules? At
least two mechanisms have been elucidated: 1. MPL-S505N
transduces the signal via the autonomous dimerisation of
the MPL protein due to strong amino acid polarity [34]
and 2. MPL-S505N leads to movement of the transmem-
brane domain and conformational changes, including tilt
and azimuthal rotational angles along the membrane axis,
which alter the conformation of the nearby intracellular do-
main and thus induce constitutive signal activation [35].
To elucidate the biologic profile of MPNs, Teofili et al.
have assessed 38 children with PV and ET [36]. How-
ever, when they conducted the MPL gene mutation a-
nalysis, they identified MPL-S505N in 9 of 11 children
with ET, thereby suggesting that these paediatric cases of
familial ET are in fact HT, which led them to question
the revised WHO diagnostic criteria for ET. To evaluate
this observation, they increased the number of children
in the study and still found erroneous diagnoses for chil-
dren with ET [37]. Therefore, they proposed that to
avoid erroneous diagnoses, the first step of the diagnos-
tic screening should be to test for MPL-S505N in those
children with thrombocythaemia who had a familial his-
tory [38]. Recently, the same group extended their study
to include 44 HT patients, including both children and
adults, and found that 22 of the 44 patients (approxi-
mately 54.5%) carried the MPL-S505N mutation. At the
median follow-up of 9 years for the 22 patients with this
mutation, they observed thrombotic manifestation in 4
cases, myocardial infarction in 7 cases, foetal loss in 2
cases, deep vein thrombosis of the leg and Budd Chiari
syndrome in 2 cases, and splenomegaly and bone mar-
row fibrosis in almost all patients. Therefore, they con-
cluded that MPL-S505N was associated with clinical
manifestations such as a significant thrombotic risk,
which, with age, evolved to splenomegaly and bone mar-
row fibrosis, thereby noticeably affecting patient life
expectancy [24]. Interestingly, most of the HT cases
reported with MPL-S505N were from Italian families;
Liu et al. have also observed this phenomenon, for which
they argue that a founder effect in Italian pedigrees with
HT may explain this occurrence [39].
MPL-K39N is a polymorphism restricted to African
Americans, and approximately 7% of African Americans
are heterozygous for this mutation [40]. In contrast,
MPL-P106L was found in approximately 6% of Arabic
individuals but not in Caucasian individuals [41]. Theseobservations may indicate ethnic specificity for these
two mutations. Both of these mutations are located
within the extracellular domain of CD110, which may
affect TPO binding, thereby leading to the defective
clearance of TPO and thus causing thrombocythaemia.
However, whether the two mutations correlate with
complications, such as thrombosis or bleeding, requires
additional statistical analysis of the data.
MPL-W515L/K associated with MPNs, RARS-t and AML
The two mutations were independently assessed because
the most recent 2008 WHO diagnostic criteria for MPNs
highlights the function of the MPL-W515L/K mutations in
the diagnosis of ET and PMF [42]. This was the first time
that these mutations appeared in the diagnostic criteria.
Although JAK2V617F is the most common mutation in
BCR-ABL-negative MPNs, approximately 50% of ET and
PMF patients are JAK2V617F-negative [43-47]. In 2006,
MPL-W515L was identified by Pikman et al., and MPL-
W515K was discovered several months later [48,49]. The
frequency rates of MPL-W515L/K in ETand PMF patients
are approximately 1% and 5%, respectively, but they are
rarely found in PV patients [48,50]. Interestingly, the pro-
portion of the MPL-W515L mutations is higher than that
of MPL-W515K mutations in MPN patients, although the
ratio of homozygous patients is lower for the MPL-
W515L mutation [51-53]. These mutations were identified
not only in granulocytes but also in monocytes, B cells, T
cells, NK cells, and even haematopoietic stem cells
[54-56]. However, increased mutation levels in the
myeloid lineage combined with the observation that
MPN is a myeloproliferative rather than a lymphoproli-
ferative disorder suggest a proliferative advantage toward
the myeloid series induced by MPL-W515 mutations [54].
The following aspects clearly indicate the close rela-
tionship between MPL-W515L/K mutations and the
pathogenesis of MPNs. 1. MPL-W515L/K mutations are
located in the unique amphipathic KWQFP motif of
CD110, which is important for preventing its spontan-
eous activation [5]. Thus, MPL-W515L/K mutations
may cause spontaneous activation. In in vitro assays, se-
veral signalling pathways were constitutively phosphory-
lated and the S phase of the cell cycle was enhanced
in MPL-W515L/K-expressing cell lines; even when de-
prived of cytokines, cytokine-independent colony forma-
tion and higher megakaryocytic cloning efficiency have
been reported [49,57]. In this process, the cytosolic tyro-
sine 112 of CD110 MPL-W515 mutants is crucial and
represents a potential target for pharmacologic inhibition
[58]. 2. In in vivo assays, the analysis of tumourigenesis in-
duction capacity of MPL-W515L/K mutants in nude mice
revealed a clinical phenomenon similar to that observed
with ET and PMF and showed atypical megakaryocytic
hyperplasia, splenomegaly and thrombocytosis [49,57,59].
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observed in normal individuals, and several studies have
indicated that MPN patients with MPL-W515L/K muta-
tions present with older age, lower haemoglobin levels and
higher platelet counts. However, the relationship between
mutation and complications, such as thrombosis, remains
unclear [51,53,60]. 4. Two MPL-W515L mutation-positive
PMF patients were treated with allogeneic stem cell trans-
plantation (allo)-SCT, and the MPL-W515L mutation was
not detected after allo-SCT and mutation status remained
negative for a long follow-up period, which is in line with
the absence of clinical or molecular relapse [61]. This ob-
servation suggests that the MPL-W515L mutation could be
used as a minimal residual disease marker and shows that
MPL-W515L plays a pathogenic role in MPN. 5. As men-
tioned above, MPL-W515L/K mutations may cause spon-
taneous signal transduction, including that of the JAK-
STAT/Crkl pathway. Moreover, various small molecule JAK
kinase inhibitors not only inhibit spontaneous activation,
thereby reducing the colony-forming capacity of cells with
MPL-W515L/K mutation in in vitro assays, but also effec-
tively relieve the symptoms observed in a MPL-W515L
murine model of MPN [59,62]. Additionally, JAK kinaseFigure 2 A proposed strategy for management of patients with throminhibitors display therapeutic value for MPN patients with
MPL-W515L/K mutations [63-65]. These observations
confirm the status of MPL-W515L/K in MPNs.
The MPL-W515L mutation has also been identified in
RARS-t and AML patient samples. Currently, RARS-t
patients harbouring the MPL-W515L mutation are rare
[66-68]. However, the mutation rate of MPL-W515L has
been found to be as high as 25% in acute megakaryoblastic
leukaemia (AMKL) with myelofibrosis, which is a subtype
of AML [69]. The MPL-W515L mutation may also be
involved in the pathogenesis of RARS-t and AML; how-
ever, as reports on this topic are sparse, the function of
the mutation in these two diseases remains uncertain.
Other MPL mutations
Due to the extremely low mutation rate and unknown
function of some mutations, we classified these muta-
tions together into one group. Compared with the MPL-
W515L/K mutations, MPL-W515A/R mutations were
found to be significantly less frequent [48,52,57]. How-
ever, it is conceivable that MPL-W515A/R mutations
function via a mechanism similar to that of the MPL-
W515L/K mutations, as they are mutations of the samebocytopenia or thrombocytosis.
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are not gain-of-function mutations, and some scholars
have hypothesised that these mutations have no rele-
vance to haematological disease or may be regulators of
other genetic events [57]. In contrast to other mutations,
MPL-T487A was observed in an acute megakaryoblastic
leukaemia (AMKL) patient and induces a myeloproli-
ferative disorder in mice by conferring the ability of
cytokine-independent cell growth [70]. The recently
detected MPL-Y252H mutation in ET also displays a
growth-promoting effect [71]. However, the function of the
MPL-Y591D, W515-P518delinsKT, S204P/F, IVS 11/12 and
IVS 10/11 mutations remains unknown [72-74].Conclusions
In conclusion, several MPL mutations have been identi-
fied in association with haematopoietic diseases. These
mutations may alter the normal regulatory mechanisms
and lead to autonomous activation or signal deficiency.
In this review, we assessed 59 different MPL mutations
and classified these mutations into four different groups
based on the associated diseases and mutation rates.
Using this classification, we clearly demonstrate the ex-
istence of four diverse types of MPL mutations and their
clinical significance. Different types of MPL mutations
induce distinct haematopoietic diseases, and the same
haematopoietic diseases may be caused by different mu-
tations. Therefore, individual treatment regimens are
required to intervene in haematopoietic disease based
on the type of mutation present. We proposed a strategy
for patients with thrombocytopenia or thrombocytosis,
especially with a family history and congenital history
(Summarised in Figure 2). For example, for patients with
thrombocytopenia, excluding secondary causes (i.e.,
medicine, infection, connective tissue diseases, hypers-
plenism or aplastic anaemia), a screening for Type 1
MPL mutations should be performed, especially for
patients with a congenital history. If a Type 1 mutation
is present, a diagnosis of congenital amegakaryocytic
thrombocytopenia can be suggested and an appropriate
therapeutic schedule can be formulated, including trans-
fusion, stem cell transplantation or even gene therapy in
the future. Otherwise, other congenital diseases should
be considered. For patients without a congenital history,
primary and exclusive diseases may be considered, such
as idiopathic thrombocytopenia purpura or other dis-
eases, and pharmacotherapy, splenectomy and other
therapies should be evaluated. When encountering pa-
tients with thrombocytosis (Sustained platelet count
> 450x109/L), excluding secondary reasons such as post-
splenectomy, malignancy, and connective tissue diseases,
Type 2 and TPO mutation screenings should be per-
formed if the patients have familial history. If thepatients test negative, a Type 3 mutation screening should
be carried out. When patients test positive for Type 2 and
TPO mutations, an HT diagnosis should be considered.
However, when patients test negative for Type 2 and TPO
mutations, sporadic thrombocythaemia should be consi-
dered while adhering to the 2008 WHO criteria [42]. Per-
haps in the near future, when a diagnosis of MPN
according to the 2008 WHO criteria is possible, JAK2
inhibitors that are currently being assessed in trials may
be available for patients.
Nevertheless, several questions regarding MPL muta-
tions remain unresolved. Why does one mutation, such
as MPL-W515L, give rise to several disease phenotypes,
namely ET, PMF, RARS-T and AML? The MPL-S505N
mutation found in HT samples is a germline mutation;
however, three acquired mutation cases were recently
reported for MPNs [53,57]. Is this a coincidental phe-
nomenon, and do other MPL mutations also possess this
property? Finally, do JAK kinase inhibitors also have
therapeutic potential for patients with MPL mutations,
such as MPL-S505N, that also cause signal activation?
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